Mylan to Pay $57 Million to Settle Drug Overpricing Claims

Mylan Inc., the generic-drug company, agreed to pay $57 million to settle claims it caused the U.S. and California to overpay for drugs.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.